Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Targeting CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer
NCT07480213Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DART-NK01, EB-DART-NK02, EB-DART-NK03 in small cell lung cancer (SCLC), sponsored by Biotech Pharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
EB-DART-NK01EB-DART-NK02EB-DART-NK03
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07480213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480213.